Trimetazidine 20mg – 30 capsules
Trimetazidine has anti-hypoxic effect. Directly affecting cardiomyocytes and neurons of the brain, optimizes their metabolism and function.
The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation).
Supports myocardial contractility, prevents reduction of intracellular ATP and creatine phosphate. Under acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and increased phosphate content due to myocardial ischemia and reperfusion. It prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic area, increases the duration of the electrical potential, reduces the yield of creatine phosphokinase from cells and the severity of ischemic myocardial damage.
With stable angina Trimetazidine reduces the frequency of attacks (reduced consumption of nitrates), after 2 weeks of treatment increases exercise tolerance, reduced sharp fluctuations in blood PRESSURE. Reduces dizziness and tinnitus.
In vascular pathology of the eye improves the functional activity of the retina.
After oral Trimetazidine rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability-90%. The time to reach C Max in plasma – 2 h. C Max after a single dose of Trimetazidine in a dose of 20 mg is about 55 ng/ml.
The plasma protein binding is 16%. Vd – 4.8 l/kg Easily passes through gistogematicalkie barriers.
T1/2 is 4.5-5 hours Excreted by the kidneys (60% – unchanged).
The renal clearance of Trimetazidine is directly correlated with KK, hepatic clearance decreases with age.
– IHD: prevention of attacks of stable angina (as part of combination therapy);
– chorioretinal disorders with ischemic component;
– cochleo-vestibular disorders of ischemic nature, such as dizziness, tinnitus, hearing impairment.
The drug is taken orally, during meals.
The recommended dose – 1 tab. (20 mg) 2-3 times/day (40-60 mg/day).
The duration of treatment is determined by the doctor.